{{Infobox medical condition
| name          = 酒精戒斷症候群
| image         = Ethanol-2D-skeletal.svg
| caption       = [[乙醇|乙醇]]
| field         = {{le|醫學毒理學|Medical Toxicology}}、{{le|成癮醫學|Addiction Medicine}}、 [[重症醫學|重症醫學]]、[[精神醫學|精神醫學]]
| symptoms      = [[焦慮症|焦慮]]、 [[顫抖|震顫]]、盜汗、[[嘔吐|嘔吐]]、[[心跳過速|心跳過速]]、輕度發燒<ref name=NICE2010/>
| complications = {{le|酒精性幻覺症|Alcoholic hallucinosis}}、[[震顫性譫妄|震顫性譫妄]]、[[癲癇發作|癲癇發作]]<ref name=NICE2010/>
| onset         = 飲酒後6小時<ref name=Sim2016/>
| duration      = 最長一週<ref name=Sim2016/>
| types         = 
| causes        = 長期大量飲酒後，減量或是停止飲酒的結果<ref name=NICE2010/>
| risks         = 
| diagnosis     = {{le|臨床機構酒精戒斷評估|Clinical Institute Withdrawal Assessment for Alcohol}} (CIWA，或是CIWA-Ar（CIWA修訂版）)<ref name=NEJM2014/>
| differential  = 
| prevention    = 
| treatment     = [[苯二氮䓬類|苯二氮䓬類]],[[硫胺|硫胺]]<ref name=Sim2016/>
| medication    = 
| prognosis     = 
| frequency     = 約5成[[酗酒|酒精使用疾患]]者在減量飲酒時會發生<ref name=NEJM2014/>
| deaths        = 
}}
 
'''酒精戒斷症候群''' ({{lang-en|Alcohol withdrawal syndrome}}（AWS）) 是在長期大量飲酒之後，減少或是停止使用而發生的一系列症狀。<ref name=NICE2010/>通常包括 [[焦慮症|焦慮]]、[[顫抖|震顫]]、盜汗、[[嘔吐|嘔吐]]、 [[心跳過速|心跳過速]]、輕度發燒。<ref name=NICE2010/>更嚴重的會發生[[癲癇|癲癇]]、[[幻覺|幻覺]]、以及[[震顫性譫妄|震顫性譫妄]](DTs)。<ref name=NICE2010>{{cite book|author1=National Clinical Guideline Centre|title=Alcohol Use Disorders: Diagnosis and Clinical Management of Alcohol-Related Physical Complications|date=2010|publisher=Royal College of Physicians (UK)|location=London|edition=No. 100|chapter-url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0047840/|access-date=21 October 2016|language=en|chapter=2 Acute Alcohol Withdrawal|url-status=live|archive-url=https://web.archive.org/web/20140131202232/http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0047840/|archive-date=31 January 2014}}</ref>症狀通常在飲酒後6小時左右開始發作，在前24至72小時內最為嚴重，7天後會有所改善。<ref name=Sim2016>{{cite journal | vauthors = Simpson SA, Wilson MP, Nordstrom K | title = Psychiatric Emergencies for Clinicians: Emergency Department Management of Alcohol Withdrawal | journal = The Journal of Emergency Medicine | volume = 51 | issue = 3 | pages = 269–73 | date = September 2016 | pmid = 27319379 | doi = 10.1016/j.jemermed.2016.03.027 }}</ref><ref name=NEJM2014/>
 
有[[酒精依賴|酒精依賴]]的人可能會發生這種戒斷症狀。<ref name=NICE2010/>發生的時機是在減少攝入酒精之後，無論減少是預先計劃或未事先計劃過。<ref name=NICE2010/>發生的機制是大腦中[[γ-氨基丁酸|γ-氨基丁酸]]受體（GABA受體）的反應性降低。<ref name=NEJM2014/>對於這種發作，通常會利用 {{le|臨床機構酒精戒斷評估|Clinical Institute Withdrawal Assessment for Alcohol}} (CIWA，或CIWA-Ar兩種)來做跟踪檢測。 <ref name=NEJM2014>{{cite journal | vauthors = Schuckit MA | title = Recognition and management of withdrawal delirium (delirium tremens) | journal = The New England Journal of Medicine | volume = 371 | issue = 22 | pages = 2109–13 | date = November 2014 | pmid = 25427113 | doi = 10.1056/NEJMra1407298 | url = http://www.escholarship.org/uc/item/08b9z9th }}</ref>
 
針對這種症狀的典型治療方式是使用[[苯二氮䓬類|苯二氮䓬類]]（如{{le|氯二氮平|chlordiazepoxide}}（商品名Librium），或[[地西泮|地西泮]]）。<ref name=Sim2016/>通常根據個人的症狀給予不同的劑量。<ref name=Sim2016/>常規建議使用的另有[[硫胺|硫胺]]素（維生素B1）。<ref name=Sim2016/>患者[[電解質不平衡|電解質不平衡]]和[[低血糖|低血糖]]的問題也要處理。<ref name=Sim2016/>早期治療可將結果改善。<ref name=Sim2016/>

在西方世界，大約有15%的人在某個時點有酒精使用疾患（[[酗酒|酗酒]]）的問題。<ref name=NEJM2014/>大約一半的酒精使用疾患患者在減少飲酒後會出現戒斷症狀，而有4%的人會出現嚴重症狀。<ref name=NEJM2014/>在那些發生嚴重症狀的人之中，會有高達15%的人死亡。<ref name=Sim2016/>被人尊稱為“醫學之父”的[[希波克拉底|希波克拉底]]早在公元前400年就描述過這種症狀。<ref>{{cite book| vauthors = Martin SC |title=The SAGE Encyclopedia of Alcohol: Social, Cultural, and Historical Perspectives|date=2014|publisher=SAGE Publications|isbn=9781483374383|page=Alcohol Withdrawal Scale|url=https://books.google.com/books?id=R9i5BgAAQBAJ&pg=PT156|language=en|url-status=live|archive-url=https://web.archive.org/web/20161022023038/https://books.google.ca/books?id=R9i5BgAAQBAJ&pg=PT156|archive-date=2016-10-22}}</ref><ref name=Kis2013/>但據信直到1700年代，這種症狀才成為種普遍的問題。<ref name=Kis2013>{{cite book| vauthors = Kissin B, Begleiter H |title=The Biology of Alcoholism: Volume 3: Clinical Pathology|date=2013|publisher=Springer Science & Business Media|isbn=9781468429374|page=192|url=https://books.google.com/books?id=hp7TBwAAQBAJ&pg=PA192|language=en|url-status=live|archive-url=https://web.archive.org/web/20161022023100/https://books.google.ca/books?id=hp7TBwAAQBAJ&pg=PA192|archive-date=2016-10-22}}</ref>
 
==體徵和症狀==
酒精戒斷的體徵和症狀主要發生在人體的[[中樞神經系統|中樞神經系統]]。戒斷的嚴重程度可從輕微的（如睡眠障礙和焦慮）到嚴重而危及生命的症狀（如酒精性幻覺、震顫性譫妄、和[[自主神經紊亂|自主神經紊亂]]）不等。<ref>{{cite journal |last= Bayard|first=Max  |last2=Jonah Mcintyre |first2= Jonah|date= 15 March 2004|title= Alcohol Withdrawal Syndrome
|url= https://www.aafp.org/afp/2004/0315/p1443.html|journal= American Family Physician|volume=69|issue= 6|pages=1443-1450 |doi= |access-date= 18 August 2021}}</ref>
 
症狀通常在飲酒後6至24小時開始。<ref name=Mun2013>{{cite journal | vauthors = Muncie HL, Yasinian Y, Oge' L | title = Outpatient management of alcohol withdrawal syndrome | journal = American Family Physician | volume = 88 | issue = 9 | pages = 589–95 | date = November 2013 | pmid = 24364635 }}</ref>可持續一週。<ref name="Mc2008"/>患者要被歸列為這種症候群，必須表現出下列症狀中的至少兩種：手顫加劇、[[失眠|失眠]]、[[噁心|噁心]]或嘔吐、短暫幻覺（聽覺、視覺、或觸覺）、{{le|心理動作性激躁|psychomotor agitation}}、焦慮、[[強直-陣攣性發作|強直-陣攣性發作]]、和自主神經紊亂。<ref name="aws" />
 
症狀嚴重程度由許多因素決定，其中最重要的是酒精攝入量、個人飲酒時間長短、以及從前酒精戒斷症狀史。<ref name="aws" />症狀也被編組和分類為：
 
*酒精性幻覺：患者發生短暫的視覺、聽覺、或觸覺上的幻覺，但其他時間則為清醒狀態。<ref name="aws" />
*戒斷性癲癇發作：這種癲癇發生在停止喝酒後的48小時內，或是有單次全身強直-陣攣性發作，或短暫但多次的發作。<ref name="Manasco">{{cite journal | vauthors = Manasco A, Chang S, Larriviere J, Hamm LL, Glass M | title = Alcohol withdrawal | url = https://archive.org/details/sim_southern-medical-journal_2012-11_105_11/page/607 | journal = Southern Medical Journal | volume = 105 | issue = 11 | pages = 607–12 | date = November 2012 | pmid = 23128805 | doi = 10.1097/smj.0b013e31826efb2d | s2cid = 25769989 }}</ref>
*震顫性譫妄：腎上腺素過多狀態、定向力障礙、震顫、盜汗、注意力/意識障礙、以及視聽幻覺。<ref name="aws" />通常在停止喝酒後24至72小時內發生。震顫性譫妄是最嚴重的戒斷症狀形式，會在5%至20%的戒酒者身上，以及在1/3的戒斷性癲癇患者身上發生。<ref name="Manasco" />
 
===症狀進展===
通常患者症狀的嚴重程度取決於之前飲酒的數量和喝酒持續時間，以及之前戒斷症狀發作的次數和嚴重程度。最嚴重的症狀，會在停止飲酒後2小時內就出現；對於這種快速發作以及嚴重程度的難預測性，必須事先規劃住院、與醫生協調治療事項，或是至少必須能儘速獲得醫療護理；在治療開始前，還應導入朋友或家人的支持系統。但在許多情況下，症狀會依據可預測的時間順序發作，如下所示：
 
喝完最後一杯後6到12小時，會出現戒斷症狀，例如顫抖、頭痛、盜汗、焦慮、噁心或嘔吐。<ref name="WebMD">{{cite web |url=http://www.webmd.com/mental-health/addiction/alcohol-withdrawal-symptoms-treatments?page=2#1 |title=Alcohol Withdrawal: Symptoms of Alcohol Withdrawal Syndrome |author=<!--Staff writer(s); no by-line.--> |website=WebMD |publisher=WebMD, LLC |access-date=28 February 2016 |url-status=live |archive-url=https://web.archive.org/web/20160304035755/http://www.webmd.com/mental-health/addiction/alcohol-withdrawal-symptoms-treatments?page=2#1 |archive-date=4 March 2016 }}</ref>在此期間也可能出現其他類似的症狀。停止喝酒後12至24小時，病情可能會發展為諸如意識模糊、幻覺<ref name="WebMD" />（有現實意識）、震顫、激動和類似疾病等主要症狀。
 
在攝入乙醇後24至48小時間，會有癲癇發作的可能。<ref name="WebMD" />
 
雖然患者的症狀通常會在48小時後開始好轉，但有時戒斷症狀會繼續加重，而成為震顫性譫妄，這種症狀的特徵包含無法把幻覺與現實區分、嚴重的困惑、癲癇發作、高血壓、以及發燒，這些症狀會持續4到12天。<ref name="WebMD" />
 
===延滯性戒斷症候群===
許多酒精使用疾患的患者，當他們戒斷症狀在急性戒斷階段症候群之後仍存在時，會出現延滯性酒精戒斷症候群，<ref>{{cite web
 | url =https://store.samhsa.gov/sites/default/files/d7/priv/sma10-4554.pdf
 | title = Substance Abuse Treatment ADVISORY News for the Treatment Field Protracted Withdrawal  
 | publisher = U.S. Department of Health and Human Services
 | date = July 2010
 | accessdate = 21 August 2021
 }}</ref>
但症狀通常是在亞急性水平，並隨時間推移而逐漸減輕。這種症候群有時被稱為急性戒斷後症候群（請參考Post-acute-withdrawal syndrome的英文版本）。一些這類症狀在戒酒後至少還會持續一年。顯示的症狀包括對酒精渴望、無法從通常令人愉快的事物中感受到愉悅（（稱為[[失樂|失樂]]））、感覺混濁、定向力障礙、噁心和嘔吐、或是頭痛。<ref name="Alcohol protracted withdrawal syndrome: the role of anhedonia"/>
 
[[失眠|失眠]]是種常見的延滯性戒斷症狀，在急性戒斷後持續存在。而失眠被發現會影響到復發率。研究發現使用[[鎂|鎂]]或[[曲唑酮|曲唑酮]]，可幫助治療延滯性戒斷症狀所產生的失眠。這些患者的失眠不易治療，因為許多傳統的助眠藥品（例如，苯二氮䓬類受體[[激動劑|激動劑]]和[[巴比妥類藥物|巴比妥類藥物]]受體激動劑）透過GABA<sub>A</sub>受體機制發生作用，會與酒精產生交叉耐受性。
 
但曲唑酮不與酒精發生交叉耐受性。<ref name="Magnesium treatment of primary alcohol-dependent patients during subacute withdrawal: an open pilot study with polysomnography"/><ref name="dpsoteotiaps"/><ref name="stoawwt"/>急性酒精戒斷症候群偶爾會發展成延滯性的。醫學文獻曾報導過酒精戒斷症狀會導致延滯性震顫性譫妄發生，但不常見。<ref name="Protracted alcohol withdrawal delirium"/>
 
==病理生理學==
長期使用酒精會導致大腦發生化學變化，尤其是在{{le|γ-氨基丁酸化|GABAergic}}的系統時。例如在[[基因表現|基因表現]]的變化和GABA<sub>A</sub>受體的下調所產生的各種適應。在急性酒精戒斷期間，也會發生變化，例如含有GABA<sub>A</sub>受體的alpha4蛋白質的上調，以及和含有GABA<sub>A</sub>受體的alpha1和alpha3兩種蛋白質的下調。用於處理急性解毒的藥物可最大程度地減少酒精戒斷期間發生的神經化學變化。這些神經化學變化可隨著把酒精以及交叉耐受藥物解除而逐漸恢復正常。<ref name="Changes in GABA(A) receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal"/><ref name="The pentylenetetrazol-like interoceptive stimulus produced by ethanol withdrawal is potentiated by bicuculline and picrotoxinin"/>{{le|N-甲基-D-天冬氨酸|NMDA}}系統發生的適應也是反復[[酒精中毒|酒精中毒]]的結果，並與酒精戒斷症候群期間中樞神經系統的過度興奮有關聯。[[高半胱氨酸|高半胱氨酸]]的水準會因長期飲酒期而升高，在戒斷狀態下會進一步升高，有導致{{le|興奮性中毒|excitotoxicity}}的可能。<ref name="Hughes-2009">{{cite journal | vauthors = Hughes JR | title = Alcohol withdrawal seizures | journal = Epilepsy & Behavior | volume = 15 | issue = 2 | pages = 92–7 | date = June 2009 | pmid = 19249388 | doi = 10.1016/j.yebeh.2009.02.037 | s2cid = 20197292 }}</ref>早期戒斷期間可能會出現[[心電圖|心電圖]]的變化（特別是{{le|QT間期|QT interval}}的增加）和[[腦電圖|腦電圖]]的異常（包括異常量化的腦電圖）。<ref name="Hughes-2009"/>[[下丘腦-垂體-腎上腺軸|下丘腦-垂體-腎上腺軸]]功能障礙和{{le|促腎上腺皮質激素釋放激素|corticotropin-releasing hormone}}增加釋放會在急性和長期戒酒期間發生，並導致急性和延滯性戒斷症狀發生。失樂症狀會持續伴隨延滯性戒斷症候群而存在，可能是因為患者[[多巴胺|多巴胺]]活性不足的結果。<ref name="pmid20148778">{{cite journal | vauthors = Heilig M, Egli M, Crabbe JC, Becker HC | title = Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? | journal = Addiction Biology | volume = 15 | issue = 2 | pages = 169–84 | date = April 2010 | pmid = 20148778 | pmc = 3268458 | doi = 10.1111/j.1369-1600.2009.00194.x }}</ref>
 
===點燃===
{{see also|{{le|點燃（鎮靜安眠藥物戒斷）|Kindling (sedative–hypnotic withdrawal|點燃}}}}

點燃是一種因為反復[[酒精解毒|酒精解毒]]，而導致戒斷併發症嚴重性增加的現象。例如，[[暴飲|暴飲]]者最初可能不會出現戒斷症狀，但隨著每次飲酒一段時間後的戒酒，而後發生的戒斷症狀會更加嚴重，最終可能導致全面性震顫性譫妄以及抽搐發作。
 
點燃會導致併發症發生，增加的風險包括復發、酒精相關[[腦損傷|腦損傷]]、以及認知缺陷。長期酒精濫用和經過多次酒精戒斷導致的點燃可能會讓GABA<sub>A</sub>受體發生永久性改變。<ref name="GABA systems, benzodiazepines, and substance dependence"/>點燃背後的機制是一些神經元系統的敏化和其他神經元系統的脫敏，而導致日漸嚴重的神經化學失衡。這反過來會導致更嚴重的戒斷症狀出現，包括焦慮、[[驚厥|驚厥]]和{{le|神經毒性|neurotoxicity}}。<ref name="autogenerated1"/>
 
暴飲與衝動性增加、[[空間記憶|空間記憶]]受損、以及情緒學習受損有關聯。這些不利的結果被認為是由於反復的戒斷症狀所產生的神經毒性作用，產生異常神經元可塑性和[[大腦皮質|大腦皮質]]的損傷。反復的急性[[酒精中毒|酒精中毒]]和急性戒酒會對大腦產生深遠的影響，並與癲癇發作和認知缺陷的風險增加有關聯。飲酒過量又經常戒酒的人與有酒精使用疾患，但又未曾戒酒過的人相比，大腦受到的影響類似，但嚴重性會較高。因此，急性戒斷症候群似乎是造成腦功能損傷或損害的最重要因素。大腦區域中最易受到酗酒傷害的是[[杏仁核|杏仁核]]和[[前額葉皮質|前額葉皮質]]兩處。<ref name="Stephens-2008"/>
 
因為暴飲而經歷過反復戒斷症狀的[[青少年|青少年]]會發生長期非語言記憶受損的情況。有酒精使用疾患的人，曾經歷過兩次或更多次戒斷症狀的，與只經歷過一次或從未有過戒斷症狀的人相比，會出現較多的[[額葉|額葉]]認知功能障礙。神經元點燃是導致與戒斷症狀相關的認知損傷的可能原因。反復戒斷症狀會導致神經適應性變化的增加。點燃也可能是暴飲者發生認知損傷的原因。<ref name="Courtney-2009"/>
 
==診斷==
許多醫院使用臨床機構酒精戒斷評估(CIWA)方案來評估患者的戒斷症狀程度，以判定所需的用藥量。<ref name=aws/>當認為是過度飲酒所造成，而對患者的飲酒史不清楚時，可經過測試{{le|缺糖型式運鐵蛋白|carbohydrate-deficient transferrin}}或是[[Γ-穀氨酰轉肽酶|Γ-穀氨酰轉肽酶]]
的升高值，來協助判斷酒精濫用和酒精依賴的程度。CIWA問巻也有精簡版（稱為CIWA-Ar），以在緊急狀況下更有效率以完成評估。<ref>{{cite journal | vauthors = Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM | title = Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) | journal = British Journal of Addiction | volume = 84 | issue = 11 | pages = 1353–7 | date = November 1989 | pmid = 2597811 | doi = 10.1111/j.1360-0443.1989.tb00737.x | citeseerx = 10.1.1.489.341 }}</ref>
 
運用苯二氮䓬類藥物治療酒精戒斷症狀，也可能會導致[[苯二氮䓬類藥物戒斷症候群|苯二氮䓬類藥物戒斷症候群]]的發生（主要由於GABA<sub>A</sub>受體的適應所引起）。

==治療==
使用苯二氮䓬類藥物可有效控制症狀，同時預防癲癇發作。<ref name="Benzodiazepines for alcohol withdrawal"/>某些維生素也是治療酒精戒斷症候群時所需的重要藥品。症狀嚴重的人通常需要住院治療。<ref name=Mun2013/>而對症狀較輕的人，可透過[[醫療衛生提供者|醫療衛生提供者]]每日到患者家中進行治療。<ref name=Mun2013/> 
 
===苯二氮䓬類藥物===
苯二氮䓬類藥物是治療酒精戒斷症狀最常用到的藥物，通常可安全及有效的把症狀壓制。<ref>{{cite journal | vauthors = Bird RD, Makela EH | title = Alcohol withdrawal: what is the benzodiazepine of choice? | url = https://archive.org/details/sim_annals-of-pharmacotherapy_1994-01_28_1/page/67 | journal = The Annals of Pharmacotherapy | volume = 28 | issue = 1 | pages = 67–71 | date = January 1994 | pmid = 8123967 | doi = 10.1177/106002809402800114 | s2cid = 24312761 }}</ref>這類藥物雖然有效，但需謹慎使用。雖然這類藥物在治療和預防戒斷症狀方面有悠久的歷史，但要選出一種最理想者，則尚未有共識。最常用的是長效性，例如{{le|氯二氮平|chlordiazepoxide}}（商品名Librium）和[[地西泮|地西泮]]。這類被認為在治療譫妄方面優於其他同類藥物，而且可間隔較長的時間施用。然而，具有中間[[半衰期|半衰期]]的同類藥物（如[[勞拉西泮|勞拉西泮]]）對有肝臟問題的人則可能比較安全。<ref name=Mc2008>{{cite journal | vauthors = McKeon A, Frye MA, Delanty N | title = The alcohol withdrawal syndrome | journal = Journal of Neurology, Neurosurgery, and Psychiatry | volume = 79 | issue = 8 | pages = 854–62 | date = August 2008 | pmid = 17986499 | doi = 10.1136/jnnp.2007.128322 | s2cid = 2139796 }}</ref>，苯二氮䓬類藥物對酒精戒斷症狀與其他常見的治療方法相比，尤其是對癲癇發作，具有較好的保護作用。<ref>{{cite journal | vauthors = Amato L, Minozzi S, Davoli M | title = Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome | journal = The Cochrane Database of Systematic Reviews | issue = 6 | pages = CD008537 | date = June 2011 | pmid = 21678378 | pmc = 7173734 | doi = 10.1002/14651858.CD008537.pub2 | url = | collaboration = Cochrane Drugs and Alcohol Group }}</ref>
 
使用長效苯二氮卓類藥物，或是短效的，其間主要爭論是在易用性。長效的，如地西泮，可把給藥頻率降低。然而確有證據顯示在“症狀導向療法”時，採用例如用勞拉西泮治療，結果同樣安全有效，但治療所需時間和用藥量同時減少。<ref name=Mc2008/>
 
雖然使用苯二氮䓬類藥物治療酒精戒斷症狀非常有效，但應謹慎使用。苯二氮䓬類藥物只能用在尚未對它發生依賴的患者，做短期使用，原因是它們與酒精具有交叉耐受性。有風險讓患者或是產生這種藥物的依賴，以取代酒精成癮，或是在酒精成癮之外再增添一種。此外，[[酒精依賴|酒精依賴]]會擾亂GABA苯二氮䓬受體功能，而且長期服用苯二氮䓬類藥物可能會妨礙患者從酒精所引起的精神疾病中完全恢復。<ref name="Changes in GABAA receptor function and cross-tolerance to ethanol in diazepam-dependent rats"/><ref name="Chronic ethanol produces a decreased sensitivity to the response-disruptive effects of GABA receptor complex antagonists"/>苯二氮䓬類藥物和酒精的組合會把彼此的不良心理影響放大，強化抑制情緒作用，並增加自殺行為，這類藥物除用於治療酒精戒斷症狀之外，通常不會做別種用途。<ref name="Alcohol use and anxiety"/>
 
===維生素===
患有酒精使用疾患的人通常缺乏各種營養素，因此在酒精戒斷症狀期間會導致嚴重的併發症，例如{{le|韋尼克-科爾薩科夫症候群|Wernicke-Korsakoff syndrome}}。為預防這種症候群的發生，患者應施用含有足夠硫胺和[[葉酸|葉酸]]的[[複合維生素|綜合維他命]]。在戒斷症狀發作時，建議在開始提供含碳水化合物的液體或食物之前，先做預防性靜脈注射硫胺、葉酸、和[[吡哆醇|吡哆醇]]。通常這些維生素保存在稱為[[香蕉袋|香蕉袋]]的容器之內。<ref name="Treatment of Alcohol Withdrawal"/>
 
===抗驚厥藥===
有甚少的證據顯示{{le|托吡酯|topiramate}}或是[[普瑞巴林|普瑞巴林]]可用於治療酒精戒斷症候群。<ref name="Hammond2015">{{cite journal | vauthors = Hammond CJ, Niciu MJ, Drew S, Arias AJ | title = Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders | journal = CNS Drugs | volume = 29 | issue = 4 | pages = 293–311 | date = April 2015 | pmid = 25895020 | pmc = 5759952 | doi = 10.1007/s40263-015-0240-4 }}</ref>有不多的證據支持使用[[加巴噴丁|加巴噴丁]]或是[[卡馬西平|卡馬西平]]治療輕度或中度症狀，或是單獨使用，或與其他藥物合併使用；但加巴噴丁似乎對重度症狀無效，因此不予推薦在此情況下使用。<ref name="Hammond2015"/><ref name="Leung2015">{{cite journal | vauthors = Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM | title = The role of gabapentin in the management of alcohol withdrawal and dependence | journal = The Annals of Pharmacotherapy | volume = 49 | issue = 8 | pages = 897–906 | date = August 2015 | pmid = 25969570 | doi = 10.1177/1060028015585849 | type = Review | s2cid = 19857498 }}</ref>[[考科蘭|考科蘭]]合作組織在2010年也發表類似報告，認為在治療酒精戒斷症狀時，支持抗驚厥藥優於苯二氮䓬類藥物的證據並不成立。<ref name="Minozzi-2010"/>[[三聚乙醛|鏈烷醛]]搭配[[水和氯醛|水和氯醛]]顯示在危及生命的副作用方面會比氯二氮平少，而卡馬西平對治療某些症狀會具有優勢。<ref name="Minozzi-2010">{{cite journal | vauthors = Minozzi S, Amato L, Vecchi S, Davoli M | title = Anticonvulsants for alcohol withdrawal | journal = The Cochrane Database of Systematic Reviews | volume = 3 | issue = 3 | pages = CD005064 | date = March 2010 | pmid = 20238337 | doi = 10.1002/14651858.CD005064.pub3 | url = http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005064/pdf_fs.html | url-status = dead | access-date = 2010-04-22 | format = PDF | veditors = Minozzi S | archive-url = https://archive.today/20130105061522/http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005064/pdf_fs.html | archive-date = 2013-01-05 }}</ref>對於之前有因戒斷症狀而癲癇發作的人，通常不推薦長期服用抗驚厥藥物。<ref name=Wise2018>{{cite web |title=American Epilepsy Society Choosing Wisely |url=http://www.choosingwisely.org/societies/american-epilepsy-society/ |website=www.choosingwisely.org |access-date=30 August 2018}}</ref>

===防止重新飲酒===
有3種藥物可協助患者防止重返飲酒的行為：{{le|那曲酮|naltrexone}}、{{le|阿坎酸|acamprosate}}、和[[雙硫侖|雙硫侖]]。使用這些藥物的時機是在戒斷症狀發生之後。<ref>{{cite web |title=Acamprosate: A New Medication for Alcohol Use Disorders |url=https://store.samhsa.gov/shin/content/MS974/MS974.pdf |access-date=8 January 2016 |date=2005 |url-status=dead |archive-url=https://web.archive.org/web/20150906045606/http://store.samhsa.gov/shin/content//MS974/MS974.pdf |archive-date=6 September 2015 }}</ref>
 
===其他===
[[可樂定|可樂定]]可與苯二氮䓬類藥物聯合使用，以緩解某些症狀。<ref name="aws" />關於{{le|貝可芬|baclofen}}在治療酒精戒斷症候群的有效性或安全性，由於證據不夠充分，加上品質不高的緣故，尚未有結論。<ref>{{Cite journal|last1=Liu|first1=Jia|last2=Wang|first2=Lu-Ning|date=August 20, 2017|title=Baclofen for alcohol withdrawal|url=https://pubmed.ncbi.nlm.nih.gov/28822350|journal=The Cochrane Database of Systematic Reviews|volume=8|pages=CD008502|doi=10.1002/14651858.CD008502.pub5|issn=1469-493X|pmc=6483686|pmid=28822350}}</ref>
 
除運用苯二氮䓬類藥物之外，有時還用到[[抗精神病藥|抗精神病藥]]（如[[氟哌啶醇|氟哌啶醇]]）以控制{{le|心理動作性激躁|psychomotor agitation}}或[[精神症|精神症]]。<ref name=aws/>抗精神病藥可能會使戒斷症狀惡化，因為這類藥物會把癲癇發作的閾值降低。貼別是[[氯氮平|氯氮平]]、[[奧氮平|奧氮平]]、或是低效[[吩噻嗪|吩噻嗪]]（如[[氯丙嗪|氯丙嗪]]）的風險很高；如果真的要使用，必須格外謹慎。 <ref name="Desk Reference for Clinical Pharmacology"/>
 
雖然理論上可使用靜脈輸入乙醇，但支持使用這種療法的證據（至少對那些病得很重的人而言）尚不足夠。<ref>{{cite journal | vauthors = Hodges B, Mazur JE | title = Intravenous ethanol for the treatment of alcohol withdrawal syndrome in critically ill patients | url = https://archive.org/details/sim_pharmacotherapy_2004-11_24_11/page/1578 | journal = Pharmacotherapy | volume = 24 | issue = 11 | pages = 1578–85 | date = November 2004 | pmid = 15537562 | doi = 10.1592/phco.24.16.1578.50945 | s2cid = 19242952 }}</ref>
 
==預後==
{{see also|預後}}
 
酒精戒斷症候群未經妥善治療，會導致永久性腦損傷，或是死亡。<ref name="pmid19670554">{{cite journal | vauthors = Hanwella R, de Silva V | title = Treatment of alcohol dependence | journal = The Ceylon Medical Journal | volume = 54 | issue = 2 | pages = 63–5 | date = June 2009 | pmid = 19670554 | doi = 10.4038/cmj.v54i2.877 | doi-access = free }}</ref>有人提出，可透過使用{{le|N-甲基-D-天門冬胺酸受體拮抗劑|NMDA receptor antagonist}}
、[[鈣離子通道阻滯劑|鈣離子通道阻滯劑]]、和{{le|糖皮質激素拮抗劑|Antiglucocorticoid}}來預防因酒精戒斷症狀所引起的腦損傷 。<ref name="Hunt-"/>
 
===妨礙復原的物質===
持續使用苯二氮䓬類藥物會妨礙由酒精引起的{{le|心理動作性遲緩|Psychomotor retardation}}和認知障礙的恢復。<ref name="Substance Use Disorders: A Practical Guide"/>[[吸菸|吸菸]]會減緩，或是干擾酒精使用疾患患者大腦通路的恢復。<ref name="Neurobiological and neurocognitive effects of chronic cigarette smoking and alcohol use disorder"/>

==參見==
{{div col|colwidth=25em}}
*[[暴飲|暴飲]]
*[[酒精依賴|酒精依賴]]
*[[喝酒的長期影響|喝酒的長期影響]]
*[[酗酒|酗酒]]
*[[酒精中毒|酒精中毒]]
*[[酒精耐受性|酒精耐受性]]
*[[酒精與健康|酒精與健康]]
*[[震顫性譫妄|震顫性譫妄]]
{{div col end}}

==資料來源 ==
{{reflist|30em|refs=

<ref name="Alcohol protracted withdrawal syndrome: the role of anhedonia">{{cite journal | vauthors = Martinotti G, Di Nicola M, Reina D, Andreoli S, Focà F, Cunniff A, Tonioni F, Bria P, Janiri L | display-authors = 6 | title = Alcohol protracted withdrawal syndrome: the role of anhedonia | journal = Substance Use & Misuse | volume = 43 | issue = 3–4 | pages = 271–84 | year = 2008 | pmid = 18365930 | doi = 10.1080/10826080701202429 | s2cid = 25872623 }}</ref>

<ref name="Alcohol use and anxiety">{{cite journal | vauthors = Ziegler PP | title = Alcohol use and anxiety | journal = The American Journal of Psychiatry | volume = 164 | issue = 8 | pages = 1270; author reply 1270-1 | date = August 2007 | pmid = 17671296 | doi = 10.1176/appi.ajp.2007.07020291 | url = http://ajp.psychiatryonline.org/cgi/content/full/164/8/1270 | url-status = live | archive-url = https://web.archive.org/web/20110612030014/http://ajp.psychiatryonline.org/cgi/content/full/164/8/1270 | archive-date = 2011-06-12 }}</ref>

<ref name="Benzodiazepines for alcohol withdrawal">{{cite journal | vauthors = Amato L, Minozzi S, Vecchi S, Davoli M | title = Benzodiazepines for alcohol withdrawal | journal = The Cochrane Database of Systematic Reviews | volume = 3 | issue = 3 | pages = CD005063 | date = March 2010 | pmid = 20238336 | doi = 10.1002/14651858.CD005063.pub3 | veditors = Amato L }}</ref>

<ref name="Changes in GABA(A) receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal">{{cite journal | vauthors = Sanna E, Mostallino MC, Busonero F, Talani G, Tranquilli S, Mameli M, Spiga S, Follesa P, Biggio G | display-authors = 6 | title = Changes in GABA(A) receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal | journal = The Journal of Neuroscience | volume = 23 | issue = 37 | pages = 11711–24 | date = December 2003 | pmid = 14684873 | pmc = 6740939 | doi = 10.1523/JNEUROSCI.23-37-11711.2003 }}</ref>

<ref name="Changes in GABAA receptor function and cross-tolerance to ethanol in diazepam-dependent rats">{{cite journal | vauthors = Toki S, Saito T, Nabeshima A, Hatta S, Watanabe M, Takahata N | title = Changes in GABAA receptor function and cross-tolerance to ethanol in diazepam-dependent rats | journal = Alcoholism, Clinical and Experimental Research | volume = 20 | issue = 1 Suppl | pages = 40A–44A | date = February 1996 | pmid = 8659687 | doi = 10.1111/j.1530-0277.1996.tb01726.x }}</ref>

<ref name="Chronic ethanol produces a decreased sensitivity to the response-disruptive effects of GABA receptor complex antagonists">{{cite journal | vauthors = Rassnick S, Krechman J, Koob GF | title = Chronic ethanol produces a decreased sensitivity to the response-disruptive effects of GABA receptor complex antagonists | url = https://archive.org/details/sim_pharmacology-biochemistry-and-behavior_1993-04_44_4/page/943 | journal = Pharmacology, Biochemistry, and Behavior | volume = 44 | issue = 4 | pages = 943–50 | date = April 1993 | pmid = 8385785 | doi = 10.1016/0091-3057(93)90029-S | s2cid = 5909253 }}</ref>

<ref name="Courtney-2009">{{cite journal | vauthors = Courtney KE, Polich J | title = Binge drinking in young adults: Data, definitions, and determinants | url = https://archive.org/details/sim_psychological-bulletin_2009-01_135_1/page/142 | journal = Psychological Bulletin | volume = 135 | issue = 1 | pages = 142–56 | date = January 2009 | pmid = 19210057 | pmc = 2748736 | doi = 10.1037/a0014414 }}</ref>

<ref name="Desk Reference for Clinical Pharmacology">{{cite book | vauthors = Ebadi M |title=Desk Reference for Clinical Pharmacology |url=https://books.google.com/books?id=ihxyHbnj3qYC |edition=2nd |date=23 October 2007 |publisher=CRC Press |location=USA |isbn=978-1-4200-4743-1 |page=512 |chapter=Alphabetical presentation of drugs}}</ref>

<ref name="GABA systems, benzodiazepines, and substance dependence">{{cite journal | vauthors = Malcolm RJ | title = GABA systems, benzodiazepines, and substance dependence | journal = The Journal of Clinical Psychiatry | volume = 64 Suppl 3 | pages = 36–40 | year = 2003 | pmid = 12662132 }}</ref>

<ref name="Hunt-">{{cite journal | vauthors = Hunt WA | title = Are binge drinkers more at risk of developing brain damage? | journal = Alcohol | volume = 10 | issue = 6 | pages = 559–61 | date = November–December 1993 | pmid = 8123218 | doi = 10.1016/0741-8329(93)90083-Z | url = https://zenodo.org/record/1258557 }}</ref>

<ref name="Magnesium treatment of primary alcohol-dependent patients during subacute withdrawal: an open pilot study with polysomnography">{{cite journal | vauthors = Hornyak M, Haas P, Veit J, Gann H, Riemann D | title = Magnesium treatment of primary alcohol-dependent patients during subacute withdrawal: an open pilot study with polysomnography | journal = Alcoholism, Clinical and Experimental Research | volume = 28 | issue = 11 | pages = 1702–9 | date = November 2004 | pmid = 15547457 | doi = 10.1097/01.ALC.0000145695.52747.BE }}</ref>

<ref name="Neurobiological and neurocognitive effects of chronic cigarette smoking and alcohol use disorder">{{cite journal | vauthors = Durazzo TC, Meyerhoff DJ | title = Neurobiological and neurocognitive effects of chronic cigarette smoking and alcoholism | journal = Frontiers in Bioscience | volume = 12 | issue = 8–12 | pages = 4079–100 | date = May 2007 | pmid = 17485360 | doi = 10.2741/2373 | url = http://www.bioscience.org/2007/v12/af/2373/fulltext.htm | url-status = live | archive-url = https://web.archive.org/web/20110525040010/http://www.bioscience.org/2007/v12/af/2373/fulltext.htm | archive-date = 2011-05-25 }}</ref>

<ref name="Protracted alcohol withdrawal delirium">{{cite journal | vauthors = Miller FT | title = Protracted alcohol withdrawal delirium | journal = Journal of Substance Abuse Treatment | volume = 11 | issue = 2 | pages = 127–30 | date = March–April 1994 | pmid = 8040915 | doi = 10.1016/0740-5472(94)90029-9 }}</ref>

<ref name="Stephens-2008">{{cite journal | vauthors = Stephens DN, Duka T | title = Review. Cognitive and emotional consequences of binge drinking: role of amygdala and prefrontal cortex | journal = Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences | volume = 363 | issue = 1507 | pages = 3169–79 | date = October 2008 | pmid = 18640918 | pmc = 2607328 | doi = 10.1098/rstb.2008.0097 }}</ref>

<ref name="Substance Use Disorders: A Practical Guide">{{cite book | vauthors = Gitlow S |title=Substance Use Disorders: A Practical Guide |url=https://books.google.com/books?id=rbrSdWVerBUC |edition=2nd |date=1 October 2006 |publisher=Lippincott Williams and Wilkins |location=USA |isbn=978-0-7817-6998-3 |pages=95–96}}</ref>

<ref name="The pentylenetetrazol-like interoceptive stimulus produced by ethanol withdrawal is potentiated by bicuculline and picrotoxinin">{{cite journal | vauthors = Idemudia SO, Bhadra S, Lal H | title = The pentylenetetrazol-like interoceptive stimulus produced by ethanol withdrawal is potentiated by bicuculline and picrotoxinin | journal = Neuropsychopharmacology | volume = 2 | issue = 2 | pages = 115–22 | date = June 1989 | pmid = 2742726 | doi = 10.1016/0893-133X(89)90014-6 }}</ref>

<ref name="Treatment of Alcohol Withdrawal">{{cite journal | vauthors = Myrick H, Anton RF |title=Treatment of Alcohol Withdrawal |journal=Alcohol Health & Research World |year=1998 |volume=22 |issue=1 |pages=38–43 |pmid=15706731 |pmc=6761817 |url=http://pubs.niaaa.nih.gov/publications/arh22-1/38-43.pdf |archive-url=https://web.archive.org/web/20101224044306/http://pubs.niaaa.nih.gov/publications/arh22-1/38-43.pdf |archive-date=2010-12-24 |url-status=live }}</ref>

<ref name="autogenerated1">{{cite journal | vauthors = Becker HC |title=Kindling in Alcohol Withdrawal |journal=Alcohol Health & Research World |volume=22 |issue=1 |year=1998 |url=http://pubs.niaaa.nih.gov/publications/arh22-1/25-34.pdf |archive-url=https://web.archive.org/web/20101215004257/http://pubs.niaaa.nih.gov/publications/arh22-1/25-34.pdf |archive-date=2010-12-15 |url-status=live }}</ref>

<ref name="aws">{{cite journal | vauthors = Bayard M, McIntyre J, Hill KR, Woodside J | title = Alcohol withdrawal syndrome | journal = American Family Physician | volume = 69 | issue = 6 | pages = 1443–50 | date = March 2004 | pmid = 15053409 | url = http://www.aafp.org/afp/20040315/1443.html | url-status = live | archive-url = https://web.archive.org/web/20081016200603/http://www.aafp.org/afp/20040315/1443.html | archive-date = 2008-10-16 }}</ref>

<ref name="dpsoteotiaps">{{cite journal | vauthors = Le Bon O, Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P | display-authors = 6 | title = Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations | journal = Journal of Clinical Psychopharmacology | volume = 23 | issue = 4 | pages = 377–83 | date = August 2003 | pmid = 12920414 | doi = 10.1097/01.jcp.0000085411.08426.d3 | s2cid = 33686593 }}</ref>

<ref name="stoawwt">{{cite journal | vauthors = Borras L, de Timary P, Constant EL, Huguelet P, Eytan A | title = Successful treatment of alcohol withdrawal with trazodone | journal = Pharmacopsychiatry | volume = 39 | issue = 6 | pages = 232 | date = November 2006 | pmid = 17124647 | doi = 10.1055/s-2006-951385 }}</ref>
}}

== 外部連結 ==
{{Medical resources
| DiseasesDB=3543
| ICD10=     {{ICD10|F|10|23|f|10}}, {{ICD10|F|10|23(0-9)|f|10}}
| ICD9=      {{ICD9|291.81}}
| MedlinePlus=000764
}}
* [http://www.mdcalc.com/ciwa-ar-for-alcohol-withdrawal/ CIWA-Ar for Alcohol Withdrawal]
* [http://www.cbhallc.com/Documents/4a-DETOX%20Guidelines.pdf Alcohol Detox Guidelines Example] {{Webarchive|url=https://web.archive.org/web/20190819081906/http://www.cbhallc.com/Documents/4a-DETOX%20Guidelines.pdf |date=2019-08-19 }}

{{模板:酒與健康}}

{{DEFAULTSORT:Alcohol Withdrawal Syndrome}}
[[分類:酒類與健康|分類:酒類與健康]]
[[分類:戒毒|分類:戒毒]]
[[分類:神經系統疾病|分類:神經系統疾病]]
[[分類:症狀和徵候：認知、知覺、情緒及行為|分類:症狀和徵候：認知、知覺、情緒及行為]]
[[分類:精神科治療|分類:精神科治療]]
[[分類:精神藥物不良反應|分類:精神藥物不良反應]]
[[Category:藥理學|Category:藥理學]]
[[Category:酗酒|Category:酗酒]]